When it comes to international opportunities, Canadian companies in the cannabis space have been proactive in attempts to create deals and partnerships with foreign companies. Few, however, have been able to fully set up shop–until now. On Monday (February 5) Cronos Group (TSXV:MJN) announced the official launch of its Australian endeavor, Cronos Australia.
Cronos Australia is a joint venture, split evenly between Cronos Group and NewSouthern Capital that will become Cronos’ hub for its planned market entrance in New Zealand and Southeast Asia.
As part of this enterprise, a new 20,000 square feet production facility will be constructed to support an annual production capacity of 2,000 kilograms. However, during an investor’s call on Monday, Cronos Group CEO Mike Gorenstein said that will be expanded in the future.
Infancy market with potential increase in patient population
Gornstein said the Australian cannabis market is still in its infancy and it resembles the Canadian one from a few years ago.
As it currently stands, Cronos plans to offer their Peace Naturals’ medicinal cannabis products–if it obtains a critical import license– to the existing patient population. As explained by Rodney Cocks, CEO, and director of the new Australian venture, this currently consists of two different groups but is hoping to expand that number.
Despite plans for increasing the patient population for medical cannabis, Cocks said currently only pediatric epilepsy and palliative care patients have access to the drug. These two groups, according to data from Deloitte in 2016, represent a little over 30,000 patients.
Cocks said he believes that number is larger now, but wouldn’t disclose how many they are in the company’s estimation. He said they will be updating those numbers in the coming months.
“I think what we’ve seen in the market is an increased rate of voices and momentum around medicinal cannabis access for patients beyond those two patient groups,” Cocks said during the investor call.
While he said the Australian market parallels that of Canada’s, Cocks explained the current Australian market has the advantage that it can mimic it faster to where it is now. “The pace of change will certainly increase,” Cocks described when comparing the two markets.
During the question period of the investor call, Matt Bottomley cannabis analyst with Canaccord Genuity asked what licenses the Australian arm of Cronos still needed. Cronos Australia holds a medicinal cannabis license and a cannabis research license.
The company is awaiting a confirmation for a manufacturing license in the next few weeks. Later asked if there could be any delays in getting a critical import license, the company said it expected no problems obtaining it.
As part of its January cannabis market update, a report issued by Canaccord indicated Cronos held a 6.9 percent share on its own cannabis index. The Canaccord Genuity Cannabis Index is comprised of 12 cannabis companies including Canopy Growth (TSX:WEED) and Aurora Cannabis (TSX:ACB) as the two largest holders with 28.6 and 26.3 percent weight respectively.
After its most recent quarterly update in November, Beacon Securities analyst Vahan Ajamian said the company’s development and production capabilities had “planted the seeds” for them to become a “true global player.”
Despite seeing an initial dip in the early trading hours, Cronos quickly increased its volume of trading. On Monday shares of Cronos closed at $7.36 per share, a 7.45 percent rise to start its trading week.
Don’t forget to follow us @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
Meanwhile, two longstanding cannabis partners ended their relationship.
Trulieve to donate $20,000 in scholarship funding and $15,000 to support leadership development
Trulieve Cannabis Corp . (CSE: TRUL) (OTC: TCNNF), a leading and top-performing cannabis company in the United States today announced a new partnership with the Thurgood Marshall College Fund (TMCF), the nation’s largest organization exclusively representing the Black College Community. Trulieve will donate $20,000 to help fund several college scholarships awarded to students who are attending one of the organization’s member-schools as part of Trulieve’s diversity, equity, and inclusion initiatives. The $15,000 in talent funding is earmarked to support TMCF’s internship program, reaching a diverse talent pool of students and alumni from their 47 member-schools to provide immersive experiences at Trulieve.
The new dispensary expands patient access to Florida’s largest inventory of medical cannabis products
Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 80th nationwide. The new location marks the Company’s first in Tamarac and third in Broward County expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion and Emergency Use Authorization Request
Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate COVID-19.
With its recent $23 million dollar financing, the Company plans to aggressively expand from 14 clinical sites to up to 50 clinical sites to meet the next enrollment goals for the Study in Q2-2020. The Study is a randomized, double-blinded, placebo-controlled trial and the safety and efficacy data analyzed at each interim analysis timepoint of 210, 400, 600 and 800 completed patients are only made available to the Independent Data and Safety Monitoring Board (“DSMB”) for review and recommendations on continuation, stopping or changes to the conduct of the Study. In the event of any serious safety concerns, the DSMB would be notified to determine any risks and provide its recommendations. To date, in this initial 210 interim point there have been no serious safety concerns that required the DSMB to be notified.
HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that its common shares have been approved for DTC full-service eligibility in the United States by the Depository Trust Company (“DTC”) and can now be both traded and serviced through DTC’s electronic book-entry system.
DTC is a subsidiary of the Depository Trust & Clearing Corp. (“DTCC”) that provides clearing and settlement services for the financial markets and settles the majority of securities transactions in the United States. This electronic method of clearing securities speeds up the receipt of stock and cash and thus accelerates the settlement process for investors and brokers, enabling the stock to be traded over a much wider selection of brokerage firms.